JO
DNTH icon

John Overdeck’s Dianthus Therapeutics DNTH Stock Holding History

John Overdeck’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
+107,455
New +$9.39M 0.01% 1489
2026
Q1 		– Sell
-48,400
Closed -$1.99M – 4657
2025
Q4 		$1.99M Buy
+48,400
New +$1.88M ﹤0.01% 2433
2025
Q1 		– Sell
-10,601
Closed -$231K – 3267
2024
Q4 		$231K Sell
10,601
-588
-5% -$15.1K ﹤0.01% 2824
2024
Q3 		$306K Buy
11,189
+689
+7% +$19.2K ﹤0.01% 2661
2024
Q2 		$272K Sell
10,500
-27,471
-72% -$660K ﹤0.01% 2639
2024
Q1 		$1.14M Buy
+37,971
New +$825K ﹤0.01% 1877
2023
Q3 		– Sell
-7,517
Closed -$91.2K – 3006
2023
Q2 		$91.2K Buy
7,517
+1,806
+32% +$20.5K ﹤0.01% 2765
2023
Q1 		$72.6K Sell
5,711
-5,922
-51% -$65.6K ﹤0.01% 2709
2022
Q4 		$73.5K Buy
11,633
+3,442
+42% +$60.9K ﹤0.01% 2547
2022
Q3 		$185K Sell
8,191
-4,407
-35% -$121K ﹤0.01% 2127
2022
Q2 		$242K Buy
12,598
+2,734
+28% +$67.6K ﹤0.01% 2100
2022
Q1 		$458K Sell
9,864
-1
-0% -$55 ﹤0.01% 2064
2021
Q4 		$699K Buy
9,865
+967
+11% +$97.2K ﹤0.01% 2903
2021
Q3 		$1.04M Sell
8,898
-1,793
-17% -$209K ﹤0.01% 2588
2021
Q2 		$1.67M Buy
10,691
+798
+8% +$147K ﹤0.01% 2022
2021
Q1 		$1.87M Sell
9,893
-2,512
-20% -$423K ﹤0.01% 1761
2020
Q4 		$1.56M Buy
12,405
+707
+6% +$80.2K ﹤0.01% 1666
2020
Q3 		$1.27M Buy
11,698
+10,973
+1,514% +$1.3M ﹤0.01% 1594
2020
Q2 		$87K Sell
725
-346
-32% -$48.7K ﹤0.01% 2800
2020
Q1 		$108K Buy
+1,071
New +$198K ﹤0.01% 2829
2019
Q1 		– Sell
-1,145
Closed -$104K – 3119
2018
Q4 		$104K Buy
+1,145
New +$156K ﹤0.01% 2806

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

John Overdeck's DNTH Position: Q2 2026 in Review

John Overdeck opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 107,455 shares worth $10.5M. The stake represents 0.01% of the portfolio and ranks #1489 among its holdings. This is a return to the name: John Overdeck previously reported a position in DNTH as recently as Q4 2025.

John Overdeck first reported a position in DNTH in Q4 2018 and has held it in 21 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • John Overdeck held 107,455 shares of Dianthus Therapeutics worth $10.5M as of Q2 2026.
  • Dianthus Therapeutics was a new John Overdeck position in Q2 2026.
  • Dianthus Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1489 holding.
  • John Overdeck first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 21 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.